Background -Until now, many investigators have focused on describing right ventricular (RV) dysfunction in groups of patients with Pulmonary Arterial Hypertension (PAH) but very few have addressed the deterioration of RV function over time. e aim of this study was to investigate time courses of RV geometric changes during the progression of RV failure. Methods -42 PAH patients were selected who underwent right heart catheterization and CMR at baseline and after 1-year follow-up. Based on the survival after this one-year run-in period, patients were classi ed into two groups: survivors (26 patients): subsequent survival of more than 4 years, and non-survivors (16 patients): subsequent survival of less than 4 years. Four-chamber cine imaging was used to quantify RV longitudinal shortening (apex-base distance change), RV transverse shortening (septum-free wall distance change), and RV fractional area change (RVFAC) between end-diastole and end-systole. Results -Longitudinal shortening, transverse shortening, and RVFAC measured at the beginning of the run-in period and 1 year later, were signi cantly higher in subsequent survivors than in non-survivors (P<0.05). Longitudinal shortening did not change during the run-in period in either patients group. Transverse shortening and RVFAC did not change during the run-in period in subsequent survivors, but decreased in subsequent non-survivors (P<0.05). is decrease was caused by increased leftward septal bowing. Conclusions -Progressive RV failure in PAH is associated with a parallel decline in longitudinal and transverse shortening until a oor e ect is reached for longitudinal shortening. A further reduction of RV function is due to progressive leftward septal displacement. Because transverse shortening incorporates both free wall and septum movements, this parameter can be used to monitor the decline in RV function in end-stage PAH.
Introduction

P
ULMONARY ARTERIAL HYPERTENSION (PAH) is a progressive and devastating disease characterized by pathological lesions of the pulmonary arteries leading to increased pulmonary artery pressure. 1 Although the pulmonary pressure rise is the distinctive characteristic of this disease, it is right ventricular (RV) function that dominates prognosis and long-term survival. 2, 3 Several geometrical measures exist that quantify RV function. RV longitudinal shortening (TAPSE) has been shown to be a good re ection of RV systolic function [4] [5] [6] . However, TAPSE only accounts for the longitudinal RV shortening and ignores the septal contribution to RV ejection. 7 Recently, our group showed that RV transverse shortening re ects global RV function at least as much as longitudinal shortening. 8 Furthermore, RV fractional area change (RVFAC) has been shown to be a robust measure of RV systolic function and has a good correlation with invasive hemodynamic data in PAH patients. 9, 10 is RVFAC has the advantage of combining transverse and longitudinal RV shortening in one measure. However, it is largely unknown how these di erent RV parameters change during the follow up of patients with progressive RV failure. erefore, the aim of this study was to evaluate the pathophysiological changes of RV geometric shortening in patients with progressive PAH, who died between 1 and 5 years after the initial diagnosis and to compare these results with stable PAH patients, surviving more than 5 years. To reach this objective, RV longitudinal and transverse shortening, as well as RVFAC, were measured in a group of PAH patients at baseline and after one year of follow-up.
Methods
Patient population e present study was performed in an observational cohort of PAH patients, and was part of a prospective ongoing research project aimed to evaluate the RV in PAH by means of MRI. Between May 2003 and May 2005, 287 patients were referred to our hospital for the evaluation of pulmonary hypertension (PH). A diagnosis of PAH was established following a standard protocol which included right heart catheterization (RHC)11. We selected treatment naïve PAH patients who underwent CMR at the time of diagnosis and again after one year of follow-up. Patients with congenital systemic-to-pulmonary shunts were excluded from this study.
In total, 42 patients were selected and grouped according to subsequent survival after the one-year run-in period: survivors (n=26) were those patients with a transplant free survival period of at least ve years after the baseline CMR. e non-survivors (n=16) were de ned as the patients who died between one and ve years after baseline CMR due to progression of the disease. Although the choice of ve years is arbitrary, this period was chosen to make a clear distinction between long and short-term survivors. In addition, previous reports and clinical experience show that patients surviving ve years can be classi ed as in a stable clinical condition, since annual mortality rate after ve years is low for this group. 12, 13 Twenty-ve patients met the diagnostic criteria for the study and survived for more than one year after diagnosis but could not be selected because they did not undergo follow-up CMR measurements (e.g. dropout, withdrawal or protocol deviators). ese patients were analyzed for potential selection bias.
Institutional Research Board approval of this protocol was obtained and all patients consented to participate in the study.
Cardiac Magnetic Resonance Imaging
CMR examination was performed using a 1.5-T Siemens Sonata MRI system (Siemens Medical Solutions, Germany), equipped with a 6-element phased-array coil. ECG-gated cine imaging was performed using a balanced steady-state free precession pulse sequence, during breath-holds. Long axis slices were acquired in the four-, three-and two-chamber views. Additionally, short axis slices were obtained with a typical slice thickness of 5 mm and a slice gap of 5 mm, fully covering both ventricles from base to apex. MR parameters 
Image analysis
Global LV and RV function analysis From the stack of short-axis cine images endocardial surfaces were carefully manually traced, using Mass Analysis software (MEDIS Medical Imaging Systems, Leiden, e Netherlands) to obtain RV and LV end-diastolic, endsystolic volumes, stroke volumes and ejection fractions. All volumetric CMR measures were corrected for body surface area (BSA). 
RV Geometric
Shortening analysis e four-chamber cine images were analyzed according to a method we described previously. 8 End-diastole was de ned as the onset of the R-wave of the ECG. End-systole was determined as the moment of end-shortening of the RV free wall (using MR cine imaging).
RV Longitudinal shortening was calculated as the distance change between end-diastole and end-systole of the tricuspid annulus to apex distance. RV Transverse shortening was calculated as the change between end-diastole and end-systole of the RV free wall to septum distance ( Figure 1 ). is transverse shortening was measured at seven di erent levels covering the whole RV cavity from base (level 1) through apex (level 7), with mid level (level 4) exactly halfway through the RV. RV free wall displacement was de ned as the displacement of the RV free wall with respect to the tricuspid annulus to apex line. Septal displacement is the displacement of the interventricular septum to the tricuspid annulus to apex line ( Figure 1 ). Positive displacement means towards the tricuspid annulus to apex line, and negative displacement means away from this line. RV fractional area change is calculated from the RV end-diastolic and end-systolic areas measured from the four-chamber view as: RVFAC = 100 × (RV end-diastolic area -RV end-systolic area) / RV end-diastolic area.
e procedural duration of post-acquisition geometric assessments depends on the number of contours, which have to be drawn. To calculate RVEF, endocardial contours are drawn at end-diastole and end-systole on all short-axis slices (generally 8 to 12). RVFAC is obtained from a single four-chamber view at end-diastole and end-systole; this process is up to 8 to 12 times faster than the determination of RVEF. For the longitudinal and transverse measures, the procedure is even simpler since it requires only single dimensions at end-diastole and end-systole.
Statistical analysis
Normal distribution of the data was veri ed using a normal probability plot and log transformed if necessary. All data are presented as mean ± SD, unless stated otherwise. Comparisons between and within groups were calculated using unpaired and paired Student t-tests. A one-way ANOVA was used when more than two groups were tested. Linear regression analysis was used to estimate the correlation between RVEF and geometric shortening measures. e sher exact test was used for categorical data.
Statistical tests were performed with SPSS software 18 (SPSS Inc, Chicago, United States). Statistical signi cance was considered when p < 0.05.
Results
Patients Characteristics
e baseline demographic and hemodynamic data of both the survivors and non-survivors are summarized in Table 1 . In 4 survivors and 4 non-survivors no RHC was performed at one-year follow-up within 2 weeks of CMR assessment. e non-survivors had a mean survival of 2.5 ± 1 year. ere was no di erence between the survivors and non-survivors with respect to age and gender. e non-survivors group contained more patients with connective tissue disease, a greater number of patients NYHA Class IV and poorer average distance 6MWT than survivors. Furthermore, cardiac output (CO) was signi cantly lower in non-survivors, but pulmonary artery pressure and PVR at baseline were similar in both groups. All patients were optimally treated and there was no signi cant di erence in the use of the PH medication between survivors and non-survivors. Figure 2 shows the hemodynamics in the subset of patients (22 survivors and 12 non-survivors) with RHC at baseline and follow-up. Although statistically not signi cant, both the survivors and non-survivors showed a reduction in PVR after one-year follow-up. Heart rate increased signi cantly during follow-up in the non-survivors. Selection bias was tested on patients without follow-up measurements (n=25: see methods). Baseline characteristics of these patients were not signi cantly di erent compared to the total study population, except for age: included patients were signi cantly younger than the patients without follow-up measurements (Table 2) .
Global RV and LV function. Figure 3 illustrates a long axis view of a survivor and a non-survivor patient at baseline in end-diastole. Compared to the survivor, the RV con guration in the non-survivor shows a markedly dilated atrium and ventricle. Volumetric and geometric CMR measurements at baseline and follow-up for the subsequent survivors and non-survivors are presented in Table 3 . RVEF at the beginning and at the end of the run-in period was signi cantly lower in non-survivors than in survivors. LV end-diastolic volume index (EDVI) and RV and LV stroke volume index (SVI) were signi cantly lower at the end of the run-in period in non-survivors than in survivors. Although baseline RVEDVI was not signi cantly di erent between the survivors and non-survivors, the RV dilated progressively during follow-up only in non-survivors. RVEF remained stable in the survivors while it further decreased in the non-survivors. 
RV Geometric Shortening
Longitudinal shortening ere was a signi cant di erence between subsequent survivors and non-survivors as shown in Figure 4A ; the non-survivors had a reduced RV longitudinal shortening as -compared to the survivors (14 ± 7 mm versus 20 ± 5 mm, P < 0.05). At follow-up, the change in RV longitudinal shortening was not signi cantly di erent between baseline and follow-up values, both for the survivors (P = 0.25) as well as the non-survivors (P = 0.13). In the non-survivors there was no signi cant correlation between the change in longitudinal shortening and change in RVEF (r =0.4, P = 0.13).
Transverse shortening e results of the transverse shortening, measured both at baseline and follow-up for the subsequent survivors and non-survivors, are given in Figure 4B . For the survivors, the RV transverse shortening did not change signi cantly at all levels between baseline and follow-up (e.g. at mid RV level: 9.7 ± 3.6 mm versus 9.5 ± 4.7 mm, P = 0.82). For the non-survivors, RV shortening at baseline was signi cantly reduced for levels two to seven as compared to the survivors (e.g. at mid RV level: 5.1 ± 5.5 mm versus -0.5 ± 5.2 mm, P < 0.001). During follow-up, the RV transverse shortening further decreased signi cantly from baseline at levels two to six and even showed lengthening at levels from mid to apex.
ere was a signi cant correlation between the change in RVEF and the change in RV transverse shortening obtained at mid level (r =0.66, P =0.005) in the non-survivors. 
RV Wall and Septal Displacement
As mentioned above, the decrease in transverse shortening at follow-up is a feature of non-survivors.
is shortening is determined by the displacements of RV free wall and septum. Note that shortening is a change of the distance between RV free wall and the septum, while displacement is an isolated property of the RV free wall and septum separately. In Figure 5 we illustrated the transverse displacements of RV free wall and septum in non-survivors separately. For the RV free wall displacement, there was no signi cant change at follow-up for any level. In contrast, for the septum there was a signi cant increase of leftward displacement for levels 2 through 7, demonstrating that the decrease in transversal shortening in progressive PAH is mainly due to worsening of leftward septum bowing.
RV fractional area change
e change in RVFAC is illustrated in Figure 6A . Similar to RV transverse shortening, the RVFAC in the survivors remained stable during one-year of follow-up. e nonsurvivors showed a decreased RVFAC at baseline already compared to the survivors (24±10 vs. 31±9%, respectively, P=0.03). At follow-up the non-survivors showed a further signi cant (P<0.001) decrease to 17±10 %. Also, there was a moderate correlation between the change in RVFAC and the change in RVEF (r =0.67, P=0.005; Figure 6B ). 
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Discussion
We investigated the pathophysiological changes in RV geometry in PAH patients in the rst year after diagnosis and related the geometric changes occurring during this initial year to subsequent survival. e major nding of this study is the following characterization of RV properties in subsequent non-survivors: 1) Longitudinal shortening and transverse shortening are already reduced at baseline; 2) Both longitudinal shortening and RV free wall motion stay the same over time in non-survivors, while transverse shortening shows a further decline over time; 3) e end-stage decline in RV function is due to a progressive leftward septal displacement, rather than due to a further decrease in RV free wall transverse or longitudinal displacement.
RV Geometric Shortening
At baseline, longitudinal and transverse shortening was signi cantly lower in subsequent non-survivors. e longitudinal shortening is comparable with the tricuspid annular plane systolic excursion (TAPSE) as used in echocardiography. 14 For a et al. 15 showed that patients with an echocardiographically derived TAPSE of less than 18 mm had a signi cantly reduced survival and an especially poor outcome was shown in those patients with a TAPSE of less than 15 mm. e reduced TAPSE of the non-survivors in the current study (mean 15 +/-6 mm) corresponds to the observations by For a et al. 15 During a one-year run-in period, we observed no further changes in longitudinal shortening in subsequent non-survivors, whereas stroke volume and RVEF showed a progressive decline in these patients.
e absence of a further loss in TAPSE in the group of non-survivors may be explained by a " oor e ect" beyond a mean TAPSE of 15 mm in the group of non-survivors. We argue that RV dysfunction may start with a loss of TAPSE and that TAPSE continues to decrease until a lower limit, or oor, is reached. During further progression of the disease, RV function may continue to deteriorate via a loss of transverse shortening. is oor e ect may also explain the absence of a signi cant correlation between the change in RVEF and change in TAPSE. However, it has been shown that clinical improvement is associated with improved TAPSE 16 . During the initial one-year of follow-up there was a signi cant reduction in transverse shortening in non-survivors, which was related to a reduction in RVEF (r=0.66, P =0.005).
e transverse shortening is composed of both displacement of the RV free wall and the septum. As for longitudinal shortening, a lower limit or oor was also reached for the RV free wall displacement in the group of non-survivors ( Figure 5) . us, increased leftward septal bowing is the main explanation for a further decline in RV transverse shortening in progressive PAH.
Recently, Marcus et al. 17 demonstrated that maximal leftward septal bowing coincides with peak RV myocardial strain. is supports the explanation that just at the moment of peak displacement of the RV free wall, the septum bows maximally to the left and thus the e ective transverse shortening is low or even negative (see Figure 4) . Since leftward septal bowing is a consequence of L-R dyssynchrony [18] [19] [20] , our nding is in line with LopezCandales et al. 21 who demonstrated in PAH patients that the presence of L-R dyssynchrony correlates well with markers of disease severity.
RVFAC combines the e ect of both longitudinal and transverse shortening in one measure, and therefore also includes septal motion. RVFAC obtained both by CMR and echocardiography has been shown to correlate well with CMR derived RVEF. 8, 9, 22 is study also showed that there was a good correlation between the change in RVFAC and the change in RVEF over a one-year period. ese results suggest that a decrease in RVFAC is an accurate re ection of RV deterioration in patients with severe PAH.
Although the change in transverse shortening correlated well with the change in RV function, it has to be noted that other factors may also contribute to RV dysfunction. Among these factors are tricuspid regurgitation and the e ect of the LV contraction on RV ejection. 23 Recently, the importance of the RV out ow tract in the determination of RV function has been also demonstrated 24 .
Clinical Implications
An important current challenge in PAH is to improve the monitoring of treatment outcomes in clinical practice and clinical trials. 25 Since prognosis in PAH is mainly determined by RV function, there is a need for simple and reproducible measures of RV function, which re ect RV deterioration over time.
is study shows that both longitudinal measures and RV free wall movements reach a lower limit in non-survivors. Clinically, the lack of improvement in longitudinal and transverse shortening of the RV free wall during treatment can be regarded as a sign of end stage RV failure. On the other hand, it is still possible that an improvement of these parameters is associated with improvement in RV function and clinical signs. 16, 26 RVFAC has the advantage that it quanti es both shortening of the RV free wall and of the septum and was shown to correlate well with global RV function. However, the tracing of the RV endocardial area by 2D echo is di cult, due to the limited range of the echo-window and the trabeculated endocardial surface. is limits the use of this measurement in clinical practice. Another parameter that quanti es leftward septal bowing is the eccentricity index, which might also be very useful.
Limitations
Some general methodological considerations apply when discussing the ndings. In this study, both the RV free wall and septal movements are determined in a 4-chamber view. It should be noted that septum bowing, if present, is less distinct in this view compared to a short axis view, because the septum is intersected near its posterior attachment to the RV and LV. In addition, the number of patients who met the diagnostic criteria, but did not receive a follow up MRI was high. ere were a variety of reasons for patients being lost to follow-up and baseline characteristics of these patients were not di erent from the other patients in this study. We therefore think it is unlikely that the outcome of our study was a ected by selection bias.
Conclusions
Progressive RV failure in PAH is associated with a parallel decline in RV longitudinal and transverse free wall displacement until a oor e ect is reached for both. A further reduction of RV function is due to progressive leftward septal displacement. Because transverse shortening incorporates both free wall and septum displacement, this parameter can be used to monitor the decline of RV function in end-stage PAH.
